This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

EDWIN M. MILLER, M.D.

AMA Arch Ophthalmol. 1956;56(6):869-877.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

It is well recognized that the light sense suffers in cases of chronic glaucoma.¹² Investigators as long as 30 years ago showed that the light minimum was considerably raised and the dark-adaptation rate retarded in cases of simple glaucoma.¹¹

The carbonic anhydrase inhibitor acetazoleamide (Diamox) has recently found widespread acceptance among ophthalmologists as a new antiglaucoma agent. The purpose of this study is to determine whether the use of acetazoleamide has a detrimental effect on the dark-adapting function of the eye suffering from glaucoma.

Method and Material

The experiment consisted of periodically determining dark-adaptation curves of six glaucoma patients, all of whom were using pilocarpine therapeutically. Once a satisfactory "base line" curve was obtained, acetazoleamide administration was begun and was continued for varying periods of time and with varying dosages. The accompanying graphs are self-explanatory. It should be pointed out, however, that the points plotted under 0 weeks . . . [Full Text PDF of this Article]

Author Affiliations
New York

From the Department of Ophthalmology of the New York University Post-Graduate Medical School.

Footnotes
Submitted for publication June 13, 1956.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?